Research Article: Therapeutic Advantage of Targeting PRMT in Combination with Chemotherapies or EGFR/HER Inhibitors in Triple-Negative Breast Cancers
Introduction:
Breast cancer is a heterogeneous disease with distinct subgroups categorized according to the expression level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER). Luminal breast cancers express ER and PR; HER-positive tumors carry an amplification of the HER gene; and triple-negative breast cancers (TNBC) do not express ER and PR and have no HER gene amplification. , Recently, about % of luminal breast cancers and % of TNBC were found to be HER-low breast…
Read more